CSL agrees to pay up to $2.3 billion for rare disease drug with Alentis

Statements (9)

1. ● Neutral

   CSL could spend up to $2.2 billion on a drug deal with a Swiss biotech start-up

   afr.comOct 5, 2026 05:41 UTC
2. ▲ Bullish

   CSL will pay $355 million upfront to co-develop Alentis' kidney and liver drug

   endpoints.newsOct 5, 2026 02:22 UTCHigh importance
3. ▲ Bullish

   CSL and Alentis Therapeutics entered into an exclusive global collaboration and co-promotion agreement to advance lixudebart

   nasdaq.comOct 5, 2026 01:10 UTCHigh importance
4. ▲ Bullish

   CSL agreed to pay Alentis Therapeutics up to US$1.55 billion to co-develop the kidney and liver disease antibody lixudebart

   businessnewsaustralia.comOct 5, 2026 00:06 UTCHigh importance
5. ● Neutral

   CSL signs a drug deal with a Swiss biotech giant to treat a rare disease

   afr.comOct 4, 2026 23:41 UTC
6. ▲ Bullish

   CSL will pay up to $2.3 billion to jointly develop and sell a rare disease drug with Alentis Therapeutics

   thewest.com.auOct 4, 2026 23:25 UTCHigh importance
7. ● Neutral

   CSL agreed to pay $1.6 billion to Alentis Therapeutics to co-develop a treatment for people with rare kidney and liver disease

   breakingthenews.netOct 4, 2026 23:25 UTCHigh importance
8. ▲ Bullish

   CSL unveils an exclusive deal with Alentis to advance rare disease treatments

   fool.com.auOct 4, 2026 22:44 UTC
9. ▲ Bullish

   CSL is entering a rare disease drug deal with Swiss firm Alentis worth up to $1.6 billion

   reuters.comOct 4, 2026 22:18 UTC